➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Colorcon
Mallinckrodt
Express Scripts

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,017,726

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,017,726
Title:Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof
Abstract: The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe.sub.3O.sub.4, Magnetite)-series ferrite superparamagnetic nanoparticle, a preparation method, and uses of carrying a physiologically-active material, a bio-material and a biomaterial for cancer hyperthermia. The iron oxide is used as a MRI contrast agent for T.sub.-2 and T.sub.2* weighted image, and the poly(organophosphazene) shows a sol-to-gel behavior depending upon the temperature change. The complex is a bound-type where the superparamagnetic ferrite nanoparticle is bonded to phosphazene-based polymer via hydrophobic binding, and a mixed-type where the superparamagnetic ferrite nanoparticle is physically mixed with the phosphazene-based polymer.
Inventor(s): Song; Soo-Chang (Seoul, KR), Kim; Jang Il (Seongnam-si, KR)
Assignee: Korea Institute of Science and Technology (Seoul, KR)
Application Number:13/173,756
Patent Claims:see list of patent claims

Details for Patent 9,017,726

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Korea Institute of Science and Technology (Seoul, KR) 2030-06-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Korea Institute of Science and Technology (Seoul, KR) 2030-06-30 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Korea Institute of Science and Technology (Seoul, KR) 2030-06-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Baxter
Boehringer Ingelheim
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.